Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03333616 · ClinicalTrials.gov registry record · Phase 2
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
A Phase 2 study of Genitourinary Cancer and Adrenocortical Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 6
- Study locations
NCT03333616 is a Phase 2 study of Genitourinary Cancer and Adrenocortical Carcinoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 100 participants, below the 1,548-participant average among 12 other Genitourinary Cancer trials with a reported enrollment target (94% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT03333616, a Phase 2 study of Genitourinary Cancer and Adrenocortical Carcinoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 6
- Study locations
Study Summary
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendocrine differentiation. Given preliminary results, the study is being tested in additional patients with bladder or upper tract carcinoma with variant histology at this time while the adrenocortical carcinoma, other rare genitourinary malignancies arms have closed to accrual -The names of the study drugs involved in this study are: * Nivolumab * Ipilimumab
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Study Locations (6)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
California
- University of California, San Diego Moores Cancer Center - La Jolla
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-12-28 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03333616
The ClinicalTrials.gov registry entry for NCT03333616 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,548-participant average among 12 other Genitourinary Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Genitourinary Cancer appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT03333616 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT03333616 about?
NCT03333616 is a clinical study titled "Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors". This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare genitourinary carcinomas and any genitourinary carcinoma with neuroendo...
What is the current status of trial NCT03333616?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2017-12-28. Estimated completion is 2026-12-31.
What conditions does trial NCT03333616 study?
This clinical trial studies the following conditions: Genitourinary Cancer, Adrenocortical Carcinoma, Penile Cancer, Non-urothelial Bladder, Non-urothelial Upper Tract.
What interventions are being tested in trial NCT03333616?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03333616?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03333616 being conducted?
This trial has 6 study locations across California, Georgia, Massachusetts, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genitourinary Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)
COMPLETED · Phase 2
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
-
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
RECRUITING
-
Discharge Medication Use Post-Operatively in GU Cancer Patients
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.